PremiumRatingsEsperion’s Strategic Growth and Product Expansion Drive Buy Rating Esperion announces plans for new research on lead development candidates Esperion to host R&D Day to highlight cardiometabolic pipeline PremiumRatingsEsperion’s Promising Future: Strategic Partnerships and Product Innovations Drive Buy Rating Sell Rating for Esperion Amidst US Market Underperformance and Competitive Pressures Esperion Therapeutics Reports Strong Revenue Growth in 2024 PremiumThe FlyEsperion reports Q4 EPS (11c), consensus (16c) Esperion’s Strategic Expansion and Growth Potential: Analyst Recommends Buy Rating Esperion partners with CSL Seqirus to commercialize NEXLETOL, NEXLIZET